Re: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer
- PMID: 24381069
- DOI: 10.1093/jnci/djt370
Re: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer
Comment on
-
Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.J Natl Cancer Inst. 2012 Dec 5;104(23):1785-95. doi: 10.1093/jnci/djs433. Epub 2012 Nov 28. J Natl Cancer Inst. 2012. PMID: 23197490 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous